Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma
Condition(s):Mantle-cell LymphomaLast Updated:May 22, 2023Not yet recruiting
Include Studies Not Open or Pending
Condition(s):Mantle-cell LymphomaLast Updated:May 22, 2023Not yet recruiting
Condition(s):Relapsed T-Cell Lymphoma; Refractory T-Cell Lymphoma; Non Hodgkin LymphomaLast Updated:December 13, 2023Recruiting
Condition(s):Classical Hodgkin Lymphoma; Relapsed Cancer; Refractory CancerLast Updated:January 10, 2023Recruiting
Condition(s):Lymphoma, Mantle-CellLast Updated:June 4, 2021Not yet recruiting
Condition(s):Myeloma MultipleLast Updated:February 7, 2024Not yet recruiting
Condition(s):Follicular LymphomaLast Updated:December 1, 2023Recruiting
Condition(s):Recurrent Follicular Lymphoma; Refractory Follicular LymphomaLast Updated:January 22, 2024Recruiting
Condition(s):Waldenstrom MacroglobulinemiaLast Updated:April 13, 2023Recruiting
Condition(s):Hodgkin LymphomaLast Updated:December 19, 2023Recruiting
Condition(s):Waldenstrom MacroglobulinemiaLast Updated:June 22, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.